Pharmaceutical Technology

JANUARY 17, 2023

Mounjaro is anticipated to launch in the US later this year or by early 2024. Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies. Bimagrumab is an activin receptor type 2B (ACVR2B or EC 2.7.11.30) antagonist that offers a unique mechanism of action within the obesity market.

Marketing 52

Marketing Patients Safety Pharmaceutical 52

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Mounjaro is the first weight loss drug to show efficacy rates comparable to surgical procedures like sleeve gastrectomies. Mounjaro is a combination of the two gut hormones GLP-1 and GIP.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Mounjaro is the first weight loss drug to show efficacy rates comparable to surgical procedures like sleeve gastrectomies. Mounjaro is a combination of the two gut hormones GLP-1 and GIP.

Medical 98

Medical Manufacturing Insurance Side effects 98